NICXF Stock - Nicox S.A.
Unlock GoAI Insights for NICXF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $7.86M | $6.90M | $3.27M | $8.58M | $14.42M |
| Gross Profit | $6.75M | $-11,503,000 | $23.56M | $7.23M | $12.91M |
| Gross Margin | 85.9% | -166.6% | 720.2% | 84.3% | 89.5% |
| Operating Income | $-9,853,646 | $-17,055,978 | $-34,061,000 | $-46,010,000 | $-6,760,000 |
| Net Income | $-22,389,639 | $-20,881,000 | $-31,285,000 | $-43,761,000 | $-18,098,000 |
| Net Margin | -284.9% | -302.5% | -956.4% | -509.9% | -125.5% |
| EPS | $-0.45 | $-0.42 | $-0.62 | $-1.17 | $-0.54 |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
Visit WebsiteEarnings History & Surprises
NICXFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q3 2025 | Jul 16, 2025 | — | — | — | — |
Q2 2025 | Apr 30, 2025 | — | $-0.28 | — | — |
Q1 2025 | Jan 23, 2025 | — | $-0.27 | — | — |
Q4 2024 | Oct 17, 2024 | — | — | — | — |
Q3 2024 | Jul 18, 2024 | — | $-0.16 | — | — |
Q2 2024 | Apr 22, 2024 | — | $-0.31 | — | — |
Q1 2024 | Jan 25, 2024 | — | $-0.46 | — | — |
Q4 2023 | Oct 20, 2023 | — | $-0.14 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 20, 2023 | — | $-0.25 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 16, 2022 | — | $-0.41 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.65 | — | — |
Q2 2022 | Apr 28, 2022 | $-0.47 | $-0.91 | -95.1% | ✗ MISS |
Q3 2021 | Sep 27, 2021 | $-0.40 | $-0.37 | +8.8% | ✓ BEAT |
Q1 2021 | Mar 1, 2021 | $-0.12 | $-0.12 | 0.0% | = MET |
Q3 2020 | Sep 10, 2020 | $-0.52 | $-0.49 | +4.3% | ✓ BEAT |
Latest News
Frequently Asked Questions about NICXF
What is NICXF's current stock price?
What is the analyst price target for NICXF?
What sector is Nicox S.A. in?
What is NICXF's market cap?
Does NICXF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NICXF for comparison